Following the release of the U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA)/Declaration on Emergency Use of Covid-19 Convalescent Plasma on August 23, 2020, and concerns raised immediately within the Michigan clinical transfusion services community, MichBio President Stephen Rapundalo issued the following statement:
August 26, 2020
· 3 min read